Key result
Cyclosporin A treatment during the early post-MI stage attenuated myocardial hypertrophy but worsened left ventricular dimensions and fractional shortening.
Why the study?
Does calcineurin inhibition by cyclosporin A affect early and late cardiac remodeling following myocardial infarction in rats?
RCT (n=45)
randomized
Does calcineurin inhibition by cyclosporin A affect early and late cardiac remodeling following myocardial infarction in rats?
Calcineurin inhibition with cyclosporin A during early post-MI remodeling attenuates compensatory hypertrophy but worsens cardiac dilation and function in a rat model.
Answers are grounded in this paper and cite their sources.
CsA effects on rat post-MI remodeling warrant clinical caution; leaves open calcineurin role in human HF.
BACKGROUND: The calcineurin-mediated signaling pathway has been implicated as one of the crucial pathways in cardiac hypertrophy. However, the role of calcineurin pathway on cardiac remodeling after myocardial infarction (MI) has not been well defined. METHODS: Infarcted rats (n = 45) were randomized into calcineurin inhibitor, cyclosporin A (CsA) or vehicle groups, 3 days after MI and treated for 2 weeks (early post-MI cardiac remodeling stage), or randomized 17 days after MI and treated for 2 weeks (late remodeling stage). RESULTS: Calcineurin pathway inhibition during the early cardiac remodeling stage attenuated the myocardial hypertrophy after MI (P < 0.05). However, left ventricular dimensions were further increased and fractional shortening deteriorated with calcineurin inhibition during this stage (P < 0.05, each). During late remodeling stage, CsA treatment did not affect myocardial hypertrophy and cardiac dilation following MI. CONCLUSION: Our results strongly support the hypothesis that calcineurin pathway mediates compensatory myocardial hypertrophy during the early remodeling stage after MI. However, the calcineurin pathway does not seem to affect the late remodeling after MI.
No takes yet. Share an insight, caveat, or question.
Youn et al. (2002) conducted an RCT in myocardial infarction (n=45). Cyclosporin A (CsA) vs. vehicle was evaluated on myocardial hypertrophy (p=< 0.05). Cyclosporin A treatment during the early post-MI stage attenuated myocardial hypertrophy but worsened left ventricular dimensions and fractional shortening.
Synapse has enriched 10 related papers. Consider them for comparative context: